The complement regulator CD46 is bactericidal to Helicobacter pylori and blocks urease activity

Gastroenterology. 2011 Sep;141(3):918-28. doi: 10.1053/j.gastro.2011.05.009. Epub 2011 May 18.

Abstract

Background & aims: CD46 is a C3b/C4b binding complement regulator and a receptor for several human pathogens. We examined the interaction between CD46 and Helicobacter pylori (a bacterium that colonizes the human gastric mucosa and causes gastritis), peptic ulcers, and cancer.

Methods: Using gastric epithelial cells, we analyzed a set of H pylori strains and mutants for their ability to interact with CD46 and/or influence CD46 expression. Bacterial interaction with full-length CD46 and small CD46 peptides was evaluated by flow cytometry, fluorescence microscopy, enzyme-linked immunosorbent assay, and bacterial survival analyses.

Results: H pylori infection caused shedding of CD46 into the extracellular environment. A soluble form of CD46 bound to H pylori and inhibited growth, in a dose- and time-dependent manner, by interacting with urease and alkyl hydroperoxide reductase, which are essential bacterial pathogenicity-associated factors. Binding of CD46 or CD46-derived synthetic peptides blocked the urease activity and ability of bacteria to survive in acidic environments. Oral administration of one CD46 peptide eradicated H pylori from infected mice.

Conclusions: CD46 is an antimicrobial agent that can eradicate H pylori. CD46 peptides might be developed to treat H pylori infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use
  • Cell Line
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Epithelial Cells / cytology
  • Epithelial Cells / metabolism
  • Epithelial Cells / microbiology
  • Gastric Mucosa / cytology
  • Gastric Mucosa / metabolism*
  • Gastric Mucosa / microbiology
  • Helicobacter Infections / drug therapy
  • Helicobacter Infections / metabolism
  • Helicobacter pylori / drug effects*
  • Helicobacter pylori / growth & development
  • Helicobacter pylori / metabolism
  • Humans
  • Membrane Cofactor Protein / metabolism
  • Membrane Cofactor Protein / pharmacology*
  • Membrane Cofactor Protein / therapeutic use
  • Mice
  • Mice, Mutant Strains
  • Peroxiredoxins / drug effects
  • Peroxiredoxins / metabolism
  • Time Factors
  • Treatment Outcome
  • Urease / drug effects*
  • Urease / metabolism*

Substances

  • Anti-Bacterial Agents
  • Membrane Cofactor Protein
  • Peroxiredoxins
  • Urease